trial · primary record
Lactium
Lactium
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2026-12-24 |
| Primary endpoint | Incidence of emergence agitation. The dose of lactium that is required to prevent the occurrence of emergence agitation in 90% of children (ED90) will be the primary aim of this study. |
| Registry ID | NCT07894484 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:55.769Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07894484
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.